Health
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3Transformational results support the potential of giredestrant to become a new standard-of-care for early-stage disease1ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment4-7Data will be featured in
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TdqKHuoAMRswPfW7YQ22wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Transformational results support the potential of giredestrant to become a new standard-of-care for early-stage disease1","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"ER-positive breast cancer accounts for approximately 70% of breast cancer cases, and up to a third experience recurrence on or after adjuvant endocrine therapy treatment4-7","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Data will be featured in an oral presentation at the 2025 San Antonio Breast Cancer Symposium and included in the official press programme","length":138,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":613,"olType":false},{"type":"text","content":"Basel, 10 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer.1 At the pre-specified interim analysis, adjuvant giredestrant significantly reduced the risk of invasive disease recurrence or death by 30% (invasive disease-free survival [iDFS]) compared with standard-of-care endocrine therapy (SoC ET) (hazard ratio [HR]=0.70, 95% confidence interval [CI] 0.57-0.87, p=0.0014).1 The lidERA results are being presented at the 2025 San Antonio Breast Cancer Symposium and are included in the official press programme.","length":791,"tagName":"p"},{"type":"text","content":"“In early ER-posi...